Positive Phase 2 Clinical Trial for Provectus Pharmaceuticals Inc. (PVCT.OB) Drug
Source: http://Blog.QualityStocks.net/?p=10955Posted on Monday, July 7th, 2008 | In Current Market News, OTCBB Markets, Small & Micro Cap, Stocks to Watch
Provectus Pharmaceuticals Inc. (PVCT.OB) is a Tennessee-based development stage pharmaceutical company that specializes in oncology and dermatology therapies. Complementing the company’s lineup of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices, and biotechnology.
In the biotechnology area, the company has developed groundbreaking technology to augment vaccine production and detect viruses. Another area that Provectus is focusing on is the dermatology space. The company is currently conducting Phase 2 clinical trials of their proprietary drug PH-10, to be used as a topical treatment for psoriasis and atopic dermatitis.
Provectus Pharma’s main focus however is in the treatment of cancer. The company is developing advanced therapies to target and destroy the deadliest cancers – melanoma, liver cancer, and breast cancer – while eliminating side effects. Clinical trials for treatment of metastatic melanoma and recurrent breast carcinoma with the company’s PV-10 drug are currently underway in Australia.
On July 7, 2008, Provectus announced that the first 25% of melanoma subjects in Australia have been treated in the company’s Phase 2 clinical trial of PV-10. If the results from these Phase 2 trials are as positive as the results were from the Phase 1 trial, the company expects to then ask the FDA for an accelerated approval. Provectus also expects to begin Phase 2 trials for PV-10 in the U.S. in the very near future.
Let us hear your thoughts below:
Last 5 posts by QualityStocks
- Omnicity Corp. (OMCY.OB) Announces Addition of New Board Member - November 20th, 2009
- Muscle Flex, Inc. (MFLI.PK) Announces Release Time for the BUDDY Tablet Caddy Two-Minute Commercial and Landing Page - November 20th, 2009
- Artfest International, Inc. (ARTS.OB) Announces Revenue Profit Jumps - November 20th, 2009
- Omnicity Corp.’s (OMCY.OB) Recently-Issued Corporate Update - November 20th, 2009
- Soligenix Inc. (SNGX.OB) Taking Steps to Meet Challenges of Vaccine Technology and Biological Warfare - November 20th, 2009
Atopic Dermatitis, biotech, Breast Cancer, Breast Carcinoma, Carcinoma, Clinical Trial, Current Market News, Development Stage, Intellectual Properties, Liver Cancer, Medical Devices, Melanoma, OTCBB Markets, Pharmaceutical Company, Pharmaceuticals Inc, Phase 1, Phase 2, Proprietary Drugs, Provectus Pharmaceuticals, Pvct, Small & Micro Cap, Stocks to Watch, Topical Treatment, Treatment Of Cancer, Vaccine Production
 About QualityStocks (http://QualityStocks.net)
Our name, QualityStocks, emphasizes our commitment to connect subscribers with companies that have huge potential to succeed in the short and long-term future. We believe strong management and vision for the future are crucial for any company to be successful. Timing is everything and we help investors succeed by providing an objective, broad-based view of the SmallCap markets on a daily basis. Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.